Neoplasm Metastasis  >>  ortataxel (BAY 59-8862)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ortataxel (BAY 59-8862) / Assertio
NCT00044525: Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

Completed
2
82
Europe, RoW
BAY59-8862 (Cytotoxic Taxane)
Bayer
Breast Neoplasms, Breast Cancer, Metastatic
02/04
02/04

Download Options